Key result
Intra-articular delivery of beta interferon using an rAAV5 vector led to a pronounced and sustained reduction in paw swelling, proteoglycan depletion, and erosions in rats.
Why the study?
Does intra-articular delivery of IFN-beta using a rAAV5 vector with an NF-kappaB promoter reduce paw swelling and joint damage in rats with adjuvant arthritis?
Does intra-articular delivery of IFN-beta using a rAAV5 vector with an NF-kappaB promoter reduce paw swelling and joint damage in rats with adjuvant arthritis?
Answers are grounded in this paper and cite their sources.
Intra-articular overexpression of IFN-beta using a rAAV5 vector with an inflammation-responsive promoter effectively reduces paw swelling and joint damage in a rat model of rheumatoid arthritis.
Beta interferon (IFN-beta) is a cytokine with potent immunomodulatory properties and has been described as a promising therapeutic molecule for the treatment of rheumatoid arthritis (RA). IFN-beta was previously overexpressed intra-articularly using an adenoviral vector in rats with adjuvant arthritis (AA) as a model of RA. This effect was powerful, albeit transient due to the vector chosen. Therefore, in the context of pre-clinical development, a delivery vector optimized for intra-articular gene transfer, recombinant adeno-associated virus type 5 (rAAV5), was selected. To exert an optimal effect, protein production should parallel the course of the disease. For this reason, the gene for IFN-beta was placed under the control of an inflammation-responsive [nuclear factor (NF)-kappaB] promoter. After intra-articular injection of the rAAV5 constructs in rats with AA, local transcription of the transgene and production of the IFN-beta protein was found, leading to a pronounced and sustained effect on paw swelling when the expression was under the control of the NF-kappaB-responsive promoter. Additionally, a significant beneficial effect was observed on proteoglycan depletion and erosions. Thus, intra-articular overexpression of IFN-beta using a rAAV5 vector exhibits potential as an innovative therapy for the treatment of RA.
No takes yet. Share an insight, caveat, or question.
Adriaansen et al. (2007) studied Adjuvant arthritis (model of rheumatoid arthritis). Intra-articular delivery of beta interferon using an rAAV5 vector was evaluated on Paw swelling, proteoglycan depletion, and erosions. Intra-articular delivery of beta interferon using an rAAV5 vector led to a pronounced and sustained reduction in paw swelling, proteoglycan depletion, and erosions in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: